Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
It is a single-center,exploratory clinical trial aimed to evaluate the objective response rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma.
Melanoma
DRUG: SHR1210|DRUG: apatinib mesylate|DRUG: Temozolomide Injection
ORR, Objective Response Rate, Through study uncompletion, an average of 1 year
It is a single-center,exploratory clinical trial aimed to evaluate the objective response rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma.